File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.ijrobp.2008.10.054
- Scopus: eid_2-s2.0-61349137589
- PMID: 19251094
- WOS: WOS:000264257400039
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Using Fluorodeoxyglucose Positron Emission Tomography to Assess Tumor Volume During Radiotherapy for Non-Small-Cell Lung Cancer and Its Potential Impact on Adaptive Dose Escalation and Normal Tissue Sparing
Title | Using Fluorodeoxyglucose Positron Emission Tomography to Assess Tumor Volume During Radiotherapy for Non-Small-Cell Lung Cancer and Its Potential Impact on Adaptive Dose Escalation and Normal Tissue Sparing |
---|---|
Authors | |
Keywords | Dose escalation Adaptive therapy Lung cancer PET |
Issue Date | 2009 |
Citation | International Journal of Radiation Oncology Biology Physics, 2009, v. 73, n. 4, p. 1228-1234 How to Cite? |
Abstract | Purpose: To quantify changes in fluorodeoxyglucose (FDG)-avid tumor volume on positron emission tomography/computed tomography (PET/CT) during the course of radiation therapy and examine its potential use in adaptive radiotherapy for tumor dose escalation or normal tissue sparing in patients with non-small-cell lung cancer (NSCLC). Methods and Materials: As part of a pilot study, patients with Stage I-III NSCLC underwent FDG-PET/CT before radiotherapy (RT) and in mid-RT (after 40-50 Gy). Gross tumor volumes were contoured on CT and PET scans obtained before and during RT. Three-dimensional conformal RT plans were generated for each patient, first using only pretreatment CT scans. Mid-RT PET volumes were then used to design boost fields. Results: Fourteen patients with FDG-avid tumors were assessed. Two patients had a complete metabolic response, and 2 patients had slightly increased FDG uptake in the adjacent lung tissue. Mid-RT PET scans were useful in the 10 remaining patients. Mean decreases in CT and PET tumor volumes were 26% (range, +15% to -75%) and 44% (range, +10% to -100%), respectively. Designing boosts based on mid-RT PET allowed for a meaningful dose escalation of 30-102 Gy (mean, 58 Gy) or a reduction in normal tissue complication probability (NTCP) of 0.4-3% (mean, 2%) in 5 of 6 patients with smaller yet residual tumor volumes. Conclusions: Tumor metabolic activity and volume can change significantly after 40-50 Gy of RT. Using mid-RT PET volumes, tumor dose can be significantly escalated or NTCP reduced. Clinical studies evaluating patient outcome after PET-based adaptive RT are ongoing. © 2009 Elsevier Inc. All rights reserved. |
Persistent Identifier | http://hdl.handle.net/10722/266892 |
ISSN | 2023 Impact Factor: 6.4 2023 SCImago Journal Rankings: 1.992 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Feng, Mary | - |
dc.contributor.author | Kong, Feng Ming | - |
dc.contributor.author | Gross, Milton | - |
dc.contributor.author | Fernando, Shaneli | - |
dc.contributor.author | Hayman, James A. | - |
dc.contributor.author | Ten Haken, Randall K. | - |
dc.date.accessioned | 2019-01-31T07:19:54Z | - |
dc.date.available | 2019-01-31T07:19:54Z | - |
dc.date.issued | 2009 | - |
dc.identifier.citation | International Journal of Radiation Oncology Biology Physics, 2009, v. 73, n. 4, p. 1228-1234 | - |
dc.identifier.issn | 0360-3016 | - |
dc.identifier.uri | http://hdl.handle.net/10722/266892 | - |
dc.description.abstract | Purpose: To quantify changes in fluorodeoxyglucose (FDG)-avid tumor volume on positron emission tomography/computed tomography (PET/CT) during the course of radiation therapy and examine its potential use in adaptive radiotherapy for tumor dose escalation or normal tissue sparing in patients with non-small-cell lung cancer (NSCLC). Methods and Materials: As part of a pilot study, patients with Stage I-III NSCLC underwent FDG-PET/CT before radiotherapy (RT) and in mid-RT (after 40-50 Gy). Gross tumor volumes were contoured on CT and PET scans obtained before and during RT. Three-dimensional conformal RT plans were generated for each patient, first using only pretreatment CT scans. Mid-RT PET volumes were then used to design boost fields. Results: Fourteen patients with FDG-avid tumors were assessed. Two patients had a complete metabolic response, and 2 patients had slightly increased FDG uptake in the adjacent lung tissue. Mid-RT PET scans were useful in the 10 remaining patients. Mean decreases in CT and PET tumor volumes were 26% (range, +15% to -75%) and 44% (range, +10% to -100%), respectively. Designing boosts based on mid-RT PET allowed for a meaningful dose escalation of 30-102 Gy (mean, 58 Gy) or a reduction in normal tissue complication probability (NTCP) of 0.4-3% (mean, 2%) in 5 of 6 patients with smaller yet residual tumor volumes. Conclusions: Tumor metabolic activity and volume can change significantly after 40-50 Gy of RT. Using mid-RT PET volumes, tumor dose can be significantly escalated or NTCP reduced. Clinical studies evaluating patient outcome after PET-based adaptive RT are ongoing. © 2009 Elsevier Inc. All rights reserved. | - |
dc.language | eng | - |
dc.relation.ispartof | International Journal of Radiation Oncology Biology Physics | - |
dc.subject | Dose escalation | - |
dc.subject | Adaptive therapy | - |
dc.subject | Lung cancer | - |
dc.subject | PET | - |
dc.title | Using Fluorodeoxyglucose Positron Emission Tomography to Assess Tumor Volume During Radiotherapy for Non-Small-Cell Lung Cancer and Its Potential Impact on Adaptive Dose Escalation and Normal Tissue Sparing | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.ijrobp.2008.10.054 | - |
dc.identifier.pmid | 19251094 | - |
dc.identifier.scopus | eid_2-s2.0-61349137589 | - |
dc.identifier.volume | 73 | - |
dc.identifier.issue | 4 | - |
dc.identifier.spage | 1228 | - |
dc.identifier.epage | 1234 | - |
dc.identifier.isi | WOS:000264257400039 | - |
dc.identifier.issnl | 0360-3016 | - |